AbsTRACT
Evaluation of bone health in childhood is important to identify children who have inadequate bone mineralisation and who may benefit from interventions to decrease their risk of osteoporosis and subsequent fracture. There are no bone protective agents that are licensed specifically for the prevention and treatment of osteoporosis in children. In this review, we discuss the mechanism of action and use of bisphosphonates and other new and established bone protective agents in children.
InTRoduCTIon
Healthy bone is metabolically active and undergoes continuous modelling and remodelling during childhood to maintain the balance between bone formation and bone resorption. The size and shape of the skeleton changes rapidly during modelling in childhood and adolescence and approximately 90% of bone mass is accrued during the first 18 years of life. 1 If this finely tuned process is disturbed, then osteoporosis can result. Osteoporosis is defined as a skeletal disorder characterised by compromised bone strength and predisposing a person to an increased risk of fracture 2 and the importance of correctly diagnosing osteoporosis in children has been highlighted by the International Society for Clinical Densitometry (ISCD). 3 The finding of one or more vertebral fracture is indicative of osteoporosis in the absence of local disease or high energy trauma. In the absence of vertebral compression, a diagnosis of osteoporosis is indicated by the presence of both a clinically significant fracture history and bone mineral density (BMD) z-score ≤2.0. 3 Skeletal fragility in children may be primary, due to an intrinsic bone abnormality (usually genetic in origin) or secondary as a result of an underlying medical condition or its treatment. Examples of conditions that can result in primary skeletal fragility include osteogenesis imperfecta, idiopathic juvenile osteoporosis and osteoporosis pseudoglioma syndrome. In most but not all cases, this skeletal fragility is associated with reduced BMD and will also satisfy the ISCD definition of osteoporosis. Secondary osteoporosis is more common and has been reported in several chronic conditions in children (see table 1 ). It may arise due to a combination of factors including the inflammatory process itself, suboptimal nutrition, reduced lean body mass, decreased physical activity, delayed puberty or due to treatment for the underlying condition, particularly glucocorticoids (GC). 4 Although there are several bone-protective agents currently used in adults with osteoporosis (see table 2), none is licensed specifically for the prevention or treatment of osteoporosis in childhood. For children with chronic illness, treatment of the underlying condition should be the mainstay of osteoporosis prevention and treatment.
bIsphosphonATes
In children, bone protective therapy has often been delivered using antiresorptive therapy, and in particular, bisphosphonates (BPs). Because a detailed review of the use of BPs in every chronic childhood condition is not possible within this article, we will focus on three examples: 1. Osteogenesis imperfecta (OI)-an example of primary skeletal fragility 2. Cerebral palsy (CP)-secondary osteoporosis related to immobility 3. Duchenne muscular dystrophy (DMD)-secondary osteoporosis associated with GC use. BPs were the first pharmacological agent to be used in children with fragility fractures. 5 Although BPs have now been widely used in adults with a range of conditions, their use in children has been more limited, in part because of concerns regarding the effects on the growing skeleton. 6 They are so called because they have two phosphonate groups, which enable them to bind to bone. They reduce osteoclast activity primarily by promoting osteoclast apoptosis and so inhibiting bone resorption. BPs also reduce overall bone turnover because bone resorption is coupled to bone formation. However, because osteoblast activity at the periosteal surface is unaffected, an overall increase in bone formation in the growing skeleton and potential reshaping of existing vertebral fractures can still occur, despite the low turnover state. 7 The newer, nitrogen-containing BPs (eg, alendronate, zoledronate, risedronate and pamidronate) work by inhibiting the enzymes within osteoclasts that are involved in the farnesyl pyrophosphate synthase and mevalonate pathways, which are important for varying aspects of osteoclast function and also inducing osteoclast apoptosis. 7 Although they have poor oral absorption, BPs have an extremely long half-life; a study of pamidronate in paediatric OI found that 2 years after cessation of treatment, bone mineral content (BMC) z-scores remained above pretreatment levels 8 and urinary excretion of pamidronate has been detected up to 8 years later. 9 This has potential implications for females of reproductive age as rodent studies have shown that BPs can cross the placenta and accumulate in the fetal skeleton causing decreased bone growth and deaths in the offspring. 10 There is, however, no evidence to date that prior BP exposure or even BP exposure during pregnancy is associated with reproductive toxicity.
Review osteogenesis imperfecta
BPs were first used in children to treat OI (the most common primary disorder of bone fragility) in 1 98 12 and are now the mainstay of treatment in this condition. The main effect of BPs in children with OI appears to be an increase in cortical bone width (a growth-dependent process that in turn improves mechanical strength) and trabecular number. The primary aim of BP treatment in OI is to reduce fracture frequency. Despite there being some evidence from a recent Cochrane review 13 that included 14 studies and 819 participants to show that either oral or cyclical intravenous BPs increase BMD in children with OI, the authors were unable to demonstrate reliable evidence of improvements in overall clinical status (reduced pain, improved growth or functional mobility). Also, while several studies independently reported a decreased fracture risk, the review could not show a consistent reduction in fracture rate after use of either oral or intravenous BP. There is growing interest in the use of oral BPs in OI, particularly in those with milder phenotypes, as they may be more cost-effective and easier to use than intravenous alternatives. 14 15 As yet, there does not appear to be sufficient evidence to favour oral agents above intravenous BPs in the acute treatment phase or in those with severe OI. 16 
secondary osteoporosis
Although BPs are now used for bone protection in many other childhood conditions, much of the justification for their use in other chronic diseases has been extrapolated from evidence in OI. A systematic review has concluded that there is insufficient evidence to recommend BPs as standard therapy for secondary osteoporosis in children because the link between increasing BMD and reducing fracture risk remains unproven. 17 The efficacy of BP therapy on BMD appears to depend on the age at time of treatment and the amount of bone growth remaining. Generally, they appear to be a safe and effective therapy in cases of severe bone loss, although the long-term effect of inhibition of bone turnover remains unknown. BPs may also ameliorate pain in certain circumstances, 18 but further work is needed to clarify this. 5 
BPs in cerebral palsy
CP is a heterogeneous group of non-progressive disorders of motor function and posture. Some patients with CP have a significant reduction in mobility and bone mass quickly diminishes without adequate bone loading. By 10 years of age, over 95% of those with non-ambulatory severe CP have osteopaenia 19 and fractures are 20% more likely in those who are non-ambulatory. First-line measures should include optimising vitamin D and calcium levels and the encouragement of weight-bearing activity. Vibration therapies have also been used, although there is only limited evidence of their effectiveness. A recent meta-analysis 20 assessing the effect of BPs on increasing BMD in children with CP found that the lumbar spine and femoral BMD z-scores were significantly higher after BP treatment compared with pretreatment values, but only one randomised controlled trial met the inclusion criteria. Furthermore, it remains unclear whether this translates to a reduction in fracture incidence, which is important when the annual fracture incidence in children with moderate-to-severe CP is 4%. 21 In addition, oromotor dysfunction and gastro-oesophageal reflux are often present in CP which may preclude the use of oral BPs.
BPs in DMD
Long-term GC use has dramatically improved the disease course in DMD. 22 GC are normally commenced once muscle function begins to plateau, usually at about 5 years of age and are Review continued through to adulthood. Growth retardation 23 and fragility fractures are important problems in DMD; it is predicted that after 100 months of GC therapy, 75% of boys will sustain a vertebral fracture. 24 Although BPs are frequently used, there is no consensus regarding timing of initiation, drug regimen or cessation of treatment. Prophylactic BP in DMD in those receiving GC has been reported to be associated with increased survival. 25 While BPs may be associated with an improvement in back pain and some vertebral reshaping, provided that the child is still growing, they do not completely prevent the development of new vertebral fractures. 26 Recent data from transiliac biopsies in boys with DMD have also shown that while BPs appear to be effective early in GC-induced bone loss, long-term use may further dampen remodelling. 27 A recent Cochrane review concluded that there was no strong evidence to guide the use of any therapy to prevent or treat GC-induced osteoporosis in boys with DMD. 28 Therefore, before considering prophylactic BP use, the potential risks must be weighed up against the benefits including consideration of the potential adverse effects of BP therapy and a decision made regarding the most appropriate time to use them. 29 
Adverse effects of bp therapy
BPs are generally well tolerated in children, 30 but as little is known of the long-term consequences of BP treatment, all patients should be regularly reviewed, looking in particular for evidence of adverse effects. An acute phase response to the initiation of intravenous BP therapy is very common, with short-lived fever and flu-like symptoms. Hypophosphataemia and hypocalcaemia can also occur. 31 Delayed bone healing after osteotomy in OI has also been described with BP use. 32 There are also three rare, but potentially serious adverse events that may be related to long-term exposure to BPs: 1. Osteonecrosis of the jaw: BP-associated osteonecrosis of the jaw (ONJ) is defined as, 'an area of exposed bone in the maxillofacial region that does not heal within 8 weeks, in a patient who is receiving or has been exposed to a BP and has not had radiation therapy to the craniofacial region'. 33 ONJ appears to be more common in adults using intravenous BPs, 34 and it has not yet been reported in a child. 35 Most cases have been documented in those receiving doses higher than prescribed for osteoporosis (eg, for malignancy) and in patients on therapy for >2 years. Experts have suggested doing any invasive dental procedures before starting treatment or suspending therapy for 3 or more months before and after such procedures, where possible, 36 although there is no evidence to support these recommendations. 2. Atypical femoral fractures: although atypical subtrochanteric femur fractures (AFF) are very rare and account for <1% of all hip/femoral fractures, they have been predominantly reported in patients taking BPs 37 and have recently been associated with BP use in a child. 38 Because BPs act by reducing bone turnover, it is possible that by preventing remodelling and effectively 'freezing' the skeleton, they allow tiny cracks to form and stress fractures to develop. AFFs occur at sites of high tensional stress, such as the lateral cortex of the proximal femoral shaft. It is also thought that those taking concomitant GCs in addition to BPs or with a genetic disposition to fracture may have a further increased risk. A large Swedish observational study of femoral fractures in postmenopausal women 39 showed that fracture rate decreased rapidly after drug withdrawal, therefore intermittent use may be favourable and a BP 'holiday' in children on long-term BPs could be considered. 3. Iatrogenic osteopetrosis: in 2003, the first case of BP-induced osteopetrosis (or marble bone disease) was described in a boy aged 12 years who had received pamidronate infusions for the previous 3 years for idiopathic bone pain and osteopaenia. 40 Abnormal oversuppression of bone remodelling (with a histological absence of osteoclasts on bone surfaces) was still present when he was followed up 7 years after cessation of BP.
Vitamin d and calcium
Vitamin D is essential for skeletal health and regulates calcium and phosphate absorption. 41 Vitamin D deficiency may be associated with decreased BMC and increased risk of rickets. 42 Children with chronic diseases are more prone to vitamin D deficiency for a variety of reasons including malabsorption, limited sunlight exposure, nutritional restrictions and the use of medications such as anticonvulsants and GCs, therefore prevention of vitamin D deficiency should be routinely considered in those with chronic illnesses. The mean dietary intake of vitamin D in children may only be about 100 IU/day 43 and therefore in the UK, the Scientific Advisory Committee for Nutrition has recommended a reference nutrient intake (RNI) of 400 IU/day for children. 43 This requirement may be even higher in those with chronic illnesses. 44 Adequate dietary calcium to meet the RNI should also be advised and supplementation considered if this is unlikely to be reached. There is no clear evidence that calcium supplementation in excess of the RNI has additional benefits on bone density while there are significant associated risks of excessive total calcium intake. Vitamin D and calcium levels should be optimised prior to the initiation of BP therapy to prevent BP-induced hypocalcaemia and maximise efficacy.
Gh and IGF-1
While there is ample evidence that the GH-IGF-1 pathway has direct effects on bone mass and strength in experimental models, 45 the effect of recombinant human GH (rhGH) on bone health in children is debatable. 46 In addition to a direct effect on osteoblast activity, it is possible that the anabolic effects of rhGH may also be mediated through an effect on lean mass, 47 alterations in PTH sensitivity 48 or even modulation of the 11-β-hydroxysteroid dehydrogenase shuttle, which is responsible for the inactivation of cortisol to cortisone. 49 Given that both rhGH and rhIGF-1 are licensed for use in children with growth disorders and in light of data from children and adults with chronic inflammation, there is potential for these anabolic agents to improve growth potential, muscle strength and bone mass in many cases of primary and secondary osteoporosis. However, before using these pharmacological agents for this purpose, an improved understanding of their effects on linear growth and bone mass, and the underlying mechanisms through which they exert their effects on bone, is imperative.
Recombinant parathyroid hormone
Teriparatide is a form of recombinant human PTH and is unique because unlike BPs, it stimulates new bone formation. It is approved for use in adults with osteoporosis and over half a million adults with severe osteoporosis have received this drug. 50 Furthermore, its anabolic effect on bone has opened up the possibility of using it in combination or sequentially with antiresorptive agents such BPs. 51 However, experimental studies have shown that almost half of the rats exposed to the highest doses Review developed osteosarcoma. 52 Despite there being many differences which make humans less susceptible than rats, 53 this risk is still of particular concern to the paediatric and adolescent population where osteosarcoma is most prevalent. However, over the last decade, there have been increasing reports of the use of recombinant PTH for intractable hypocalcaemia associated with hypoparathyroidism in children. 54 
sex steroids
Growth and pubertal development are often impaired in chronic disease and the pubertal process and associated GH surge are vital to increase bone size and bone mineral accrual. Androgen deficiency is a recognised risk factor for osteoporosis and fracture and evidence suggests that early initiation of androgen therapy is associated with improved BMD in adults. 55 However, precocious puberty or treatment with high doses of either oestrogen or testosterone can paradoxically cause premature fusion of the epiphyses and a subsequent reduction in final height. 56 Oxandrolone, an anabolic steroid that is only weakly androgenic and does not aromatise, has been studied in children with severe burns. It has been reported to increase bone mass, 57 but is often not readily available. Physiological oestrogen replacement given transdermally (so not to inhibit IGF-1 production) alongside cyclical progesterone has also been shown to increase bone mineral accrual in teenagers with anorexia 58 and the American College of Sports Medicine recommends that oral contraceptives be considered in amenorrhoeic athletes over 16 years of age if BMD is declining despite sufficient weight gain.
59
Alternative agents for consideration Receptor activator of nuclear factor-k-B ligandinhibitors Denosumab is a monoclonal antibody to the receptor activator of nuclear factor-k-B ligand (RANKL), a key mediator of osteoclast activity. It is given subcutaneously and targets the RANKL (figure 1), thus inhibiting osteoclast-mediated bone resorption and increasing BMD. There is extensive data to show its efficacy in postmenopausal osteoporosis 60 and it has also been used in a group of children with OI. 61 However, its efficacy and side-effect profile is not clearly understood in children and there may be an increased risk of calcium dysregulation, so further studies are warranted. 62 
Sclerostin antibody
Sclerostin is produced by osteocytes (figure 1) and probably acts as antagonist of the Wnt signalling pathway to inhibit bone formation, although the exact mechanism remains unclear. 63 Neutralisation of sclerostin using monoclonal antibodies in a mouse model of OI, resulted in improved bone mass and reduced long bone fragility 64 and early clinical studies in adults have shown similar results. 65 Sclerostin antibodies have also been used to prevent GC-induced trabecular and cortical bone loss in mouse models of GC-induced osteoporosis. 66 
Cathepsin K inhibitors
Cathepsin K is a cysteine protease that is highly expressed by osteoclasts and degrades type 1 collagen 67 ( figure 1 ). Cathepsin K inhibitors are thought to reduce bone resorption while also increasing the number of cells of osteoclast lineage and therefore not suppressing bone formation to the same degree as BPs. Cathepsin K inhibitors such as odanacatib have shown promising efficacy data, 68 but an increased risk of atrial fibrillation and stroke in adult phase III trials has meant that marketing of these agents has now been halted.
ConClusIon
Alongside consideration of pharmacological approaches to maximise bone accrual, optimising nutritional factors and encouraging activity, within the constraints of the disease process are also important. Timely pubertal assessment should be performed in those with chronic disease and where appropriate, puberty induced. Optimal management includes regular screening to identify those at risk of fracture and then aiming to treat earlier, rather than waiting for fragility fractures to occur, particularly in those who have little potential for spontaneous recovery.
There is still limited evidence for the use of bone protective agents in most childhood conditions and although BPs are commonly used, evidence for their efficacy remains limited. Most studies are small and only have limited follow-up and there is no consensus on the length of BP treatment regimens and dosage in children. Long-term safety needs to be assessed by large-scale trials with extended follow-up; the rarity of many conditions under study may necessitate international collaborative efforts. Many studies also use change Figure 1 Schematic diagram to show the mechanism of action of bone protective agents. Bisphosphonates (BPs) act at the osteoclast to reduce bone resorption. Recombinant parathyroid hormone (PTH), eg, teriparatide promotes bone formation. Sclerostin is secreted by osteocytes; sclerostin antibody binds to circulating sclerostin and so enables Wnt signalling of osteoprogenitors and osteoblasts. Receptor activator of nuclear factork-B ligand (RANKL) antibodies (eg, denosumab) target the RANK ligand and prevent bone resorption at the osteoclast. Cathepsin K inhibitors (eg, odanacatib) prevent release of enzymes that degrade collagen at the osteoclast.
Review
in BMD as primary outcome but the extent of correlation with this and subsequent fracture rate remain unclear and age-appropriate reference ranges are not commonly available for very young children. As antiresorptives result in a low bone-turnover state with an associated reduction in bone formation and hence reduced overall bone remodelling, it would clearly be advantageous to find safe and effective anabolic agents to use in the paediatric population, either alone or in combination and this must remain a research priority.
